Quantifying Huntingtin Protein in Human Cerebrospinal Fluid Using a Novel Polyglutamine Length-Independent Assay

BACKGROUND: The use of biomarkers has become a major component of clinical trial design. In Huntington’s disease (HD), quantifying the amount of huntingtin protein (HTT) in patient cerebrospinal fluid (CSF) has served as a pharmacodynamic readout for HTT-lowering therapeutic approaches and is a pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Fodale, Valentina, Pintauro, Roberta, Daldin, Manuel, Spiezia, Maria Carolina, Macdonald, Douglas, Bresciani, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535588/
https://www.ncbi.nlm.nih.gov/pubmed/35938256
http://dx.doi.org/10.3233/JHD-220527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535588/
https://www.ncbi.nlm.nih.gov/pubmed/35938256
http://dx.doi.org/10.3233/JHD-220527

Ejemplares similares